Quince Therapeutics
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -36 | -36 | |
EBITDA | 30,609 | -11,328 | |
EBIT | 30,573 | -11,364 | |
Net Income | 35,912 | -39,458 | -13,442 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -7,627 | -10,485 | -10,002 |
Cash | 18,163 | 5,809 | 6,452 |
Basic Shares | 250 | 278 | 269 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -142 | -186 | -322 | -175 |
EBITDA | -80,623 | -35,984 | -26,820 | -50,986 |
EBIT | -80,765 | -36,170 | -27,142 | -51,190 |
Net Income | -83,979 | -56,828 | -31,385 | -51,660 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -25,329 | |||
Free Cash Flow | -41,777 | -32,161 | -18,452 | -44,171 |
Cash | 5,809 | 6,212 | 20,752 | 44,579 |
Basic Shares | 250 | 216 | 186 | 167 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$12.31 |
2026-03-31 | -$152 |
2025-12-31 | -$0.40 |
2025-09-30 | -$50 |